Press releaseGlobe Newswire
CAMP4 Therapeutics
CAMP · NASDAQ
$3.16+$0.02 (+0.64%)TodayMarket closed ·
Prev close $3.14
Latest news
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
CAMP4 Therapeutics Receives MHRA Authorization To Include UK Sites In Global Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic Candidate For Patients With SYNGAP1-Related Disorder
- Press releaseGlobe Newswire
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
- News
CAMP4 Therapeutics To Host Virtual Analyst Day To Demonstrate CMP-002 Data To Treat SYNGAP1-Related Disorder
- Press releaseGlobe Newswire
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
- Press releaseGlobe Newswire
CAMP4 to Participate in Upcoming Investor Conferences
- Press releaseGlobe Newswire
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
- Press releaseGlobe Newswire
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
- News
CAMP4 Therapeutics Receives Clearance From Australia’s TGA And Local HREC To Initiate Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic For SYNGAP1-Related Disorder
- Press releaseGlobe Newswire
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
Camp4 Therapeutics Earnings Review: Q4 Summary
- NewsVandana Singh
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releaseGlobe Newswire
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Why ThredUp Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseGlobe Newswire
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
- NewsAvi Kapoor
Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
- NewsVandana Singh
CAMP4 Analyst Highlights Rare Disease Platform Potential
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.